The IBN SINA Pharmaceutical Industry PLC Stock price

Equities

IBNSINA

BD0464IBNSN2

Pharmaceuticals

End-of-day quote Dhaka S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
258.1 BDT -0.73% Intraday chart for The IBN SINA Pharmaceutical Industry PLC -1.68% -9.94%
Sales 2024 * 11.18B 102M Sales 2025 * 12.74B 116M Capitalization 8.06B 73.34M
Net income 2024 * 685M 6.23M Net income 2025 * 777M 7.07M EV / Sales 2024 * 0.72 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.63 x
P/E ratio 2024 *
11.8 x
P/E ratio 2025 *
10.4 x
Employees 4,000
Yield 2024 *
2.63%
Yield 2025 *
2.98%
Free-Float 47.44%
More Fundamentals * Assessed data
Dynamic Chart
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the Full Year Ended June 30, 2023 CI
The IBN SINA Pharmaceutical Industry Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
The IBN SINA Pharmaceutical Industry Ltd. has Changed its Name to The IBN SINA Pharmaceutical Industry PLC CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
The IBN SINA Pharmaceutical Industry PLC Reports Earnings Results for the Full Year Ended June 30, 2022 CI
The IBN SINA Pharmaceutical Industry Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022 CI
The IBN SINA Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
The IBN SINA Pharmaceutical Industry Ltd. to Build Central Store at Gazipur CI
The IBN SINA Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
The IBN SINA Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
The IBN SINA Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021 CI
More news
1 day-0.73%
1 week-1.68%
Current month-4.76%
1 month-5.35%
3 months-9.94%
6 months-9.94%
Current year-9.94%
More quotes
1 week
258.00
Extreme 258
265.00
1 month
257.00
Extreme 257
278.90
Current year
257.00
Extreme 257
286.60
1 year
257.00
Extreme 257
291.70
3 years
230.00
Extreme 230
348.00
5 years
192.00
Extreme 192
348.00
10 years
61.32
Extreme 61.3216
348.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 02-12-31
Director of Finance/CFO 70 12-12-31
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 76 82-12-31
Director/Board Member 64 22-01-15
Chief Executive Officer 68 02-12-31
More insiders
Date Price Change Volume
24-03-28 258.1 -0.73% 5,856
24-03-27 260 -0.42% 13,647
24-03-25 261.1 -0.11% 28,805
24-03-24 261.4 -0.42% 5,292
24-03-21 262.5 +0.92% 21,833

End-of-day quote Dhaka S.E., March 27, 2024

More quotes
The IBN SINA Pharmaceutical Industry Ltd is a pharmaceutical company in Bangladesh. The Company is engaged in the production of pharmaceutical drugs and natural medicines. It sells its products to both local and international market. The Company offers its products in a range of therapeutic areas, such as anti-allergic occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, antifungal, anti-glucoma, anti-histamine, anti-malarial, anti-protozoal, antibiotic, antivertigo agent, antiviral, cough expectorant, dry eye syndrome, hormone products, nasal decongestant, topical, urinary incontinence and sterois-occular. The Company offers its products under various brand names, such as Aceril, Acipam, Algirex, Azopt, Antigrain, Bactin, Betasil, Buscon, Bromofen, Camide, Cardil, Cloram-D, Cinarzin, Dermacort, Dexon, Donadin, Emiston, Eylon, Fexomin, Fungin, Fruson, Gatsina, Glamor, Hexyclore, Iluca, Inseac, Ketof, Lansina, Lytex, Malex, Metsina, Natazol and Neuralgin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
258.1 BDT
Average target price
370 BDT
Spread / Average Target
+43.36%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock The IBN SINA Pharmaceutical Industry PLC - Dhaka S.E.